E. Ohman J or Asset Management AB Sells 1,480 Shares of Regeneron Pharmaceuticals, Inc. $REGN

E. Ohman J or Asset Management AB lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 34.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 2,840 shares of the biopharmaceutical company’s stock after selling 1,480 shares during the period. E. Ohman J or Asset Management AB’s holdings in Regeneron Pharmaceuticals were worth $2,192,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of REGN. Dodge & Cox raised its stake in Regeneron Pharmaceuticals by 64.6% in the second quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock worth $2,008,799,000 after buying an additional 1,502,198 shares in the last quarter. Norges Bank purchased a new stake in Regeneron Pharmaceuticals during the second quarter worth $628,151,000. AQR Capital Management LLC boosted its position in Regeneron Pharmaceuticals by 528.7% during the 3rd quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company’s stock valued at $405,596,000 after acquiring an additional 606,612 shares in the last quarter. Invesco Ltd. boosted its position in Regeneron Pharmaceuticals by 38.0% during the 3rd quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock valued at $834,675,000 after acquiring an additional 408,649 shares in the last quarter. Finally, Loomis Sayles & Co. L P increased its holdings in shares of Regeneron Pharmaceuticals by 18.6% in the 2nd quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock valued at $1,019,062,000 after acquiring an additional 305,089 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the sale, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. This represents a 46.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the sale, the senior vice president owned 4,272 shares in the company, valued at $3,325,837.44. The trade was a 32.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 5,274 shares of company stock worth $4,142,738 in the last 90 days. Corporate insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $741.69 on Wednesday. The stock has a 50-day moving average of $764.37 and a two-hundred day moving average of $704.03. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $821.11. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. The stock has a market cap of $78.41 billion, a P/E ratio of 17.85, a P/E/G ratio of 1.98 and a beta of 0.41.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period in the prior year, the company earned $12.07 earnings per share. The company’s revenue was up 2.5% on a year-over-year basis. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Investors of record on Friday, February 20th were issued a $0.94 dividend. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date was Friday, February 20th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.05%.

Analyst Upgrades and Downgrades

REGN has been the subject of several recent research reports. Bank of America raised Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and boosted their price target for the stock from $627.00 to $860.00 in a research report on Wednesday, January 7th. Wall Street Zen downgraded Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Cantor Fitzgerald boosted their target price on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Guggenheim increased their price target on shares of Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Finally, Zacks Research cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $802.27.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Sanofi & Regeneron’s Dupixent (dupilumab) was approved in Japan as the first targeted treatment for adults with bullous pemphigoid (BP). Approval was based on pivotal data showing over four times more Dupixent patients achieved sustained remission through Week 36 vs placebo; this is Dupixent’s seventh approved indication in Japan and expands its commercial footprint and near‑term revenue potential in a new specialty indication. Dupixent Japan Approval (GlobeNewswire)
• Neutral Sentiment: Multiple short‑interest reports show a reported increase in March but list short interest as 0 shares and “NaN” changes — producing a days‑to‑cover of 0.0. This appears to be a data/reporting anomaly and is unlikely to be a meaningful driver for the stock until clearer short‑interest figures are published.
• Negative Sentiment: Apogee Therapeutics reported Phase 2 data for a long‑acting eczema therapy (zumilokibart) that supports dosing every 3–6 months; Apogee shares jumped ~20% on the news. If that program advances, it represents a potential long‑term competitive threat to Dupixent in atopic dermatitis and could pressure future market share or pricing in certain segments. Apogee Phase 2 results (BioPharmaDive)

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.